Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling. - Wikidata - wikimedia - TriplyDB

Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling.

Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling.

http://www.wikidata.org/entity/Q37041173

about

Targeting the latent reservoir to achieve functional HIV cure Epigenetic control of HIV-1 post integration latency: implications for therapy Manipulation of the host protein acetylation network by human immunodeficiency virus type 1 Targeting NF-κB signaling with protein kinase C agonists as an emerging strategy for combating HIV latency Targeting the Brain Reservoirs: Toward an HIV Cure Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression HIV Exploits Antiviral Host Innate GCN2-ATF4 Signaling for Establishing Viral Replication Early in Infection Advancements in Developing Strategies for Sterilizing and Functional HIV Cures.Chemical probes targeting epigenetic proteins: Applications beyond oncology.Progress towards an HIV cure: update from the 2014 International AIDS Society Symposium Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.Single-Cell Characterization of Viral Translation-Competent Reservoirs in HIV-Infected Individuals Euphorbia Kansui Reactivates Latent HIV.Molecular mechanisms of HIV latency.Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-1 Latency Reversal Opposite transcriptional regulation of integrated vs unintegrated HIV genomes by the NF-κB pathway.The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function HMBA Enhances Prostratin-Induced Activation of Latent HIV-1 via Suppressing the Expression of Negative Feedback Regulator A20/TNFAIP3 in NF-κB Signaling HIC1 controls cellular- and HIV-1- gene transcription via interactions with CTIP2 and HMGA1.Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo.International AIDS Society global scientific strategy: towards an HIV cure 2016.Mixed effects of suberoylanilide hydroxamic acid (SAHA) on the host transcriptome and proteome and their implications for HIV reactivation from latency.Progress and challenges in the use of latent HIV-1 reactivating agents Challenges and strategies for the eradication of the HIV reservoir.13-Oxyingenol dodecanoate, a cytotoxic ingenol derivative, induces mitochondrial apoptosis and caspase-dependent Akt decrease in K562 cells.Current views on HIV-1 latency, persistence, and cure.The therapeutic landscape of HIV-1 via genome editing A chalcone derivative reactivates latent HIV-1 transcription through activating P-TEFb and promoting Tat-SEC interaction on viral promoter.Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui.Reactivation of simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques.Natural products and HIV/AIDS.Tools for Visualizing HIV in Cure Research.Compounds producing an effective combinatorial regimen for disruption of HIV-1 latency.Beyond the replication-competent HIV reservoir: transcription and translation-competent reservoirs.HIV latency is reversed by ACSS2-driven histone crotonylation.Novel Latency Reversal Agents for HIV-1 Cure.

P2860

Q26745923-32AA5832-88E2-4357-8849-DD43AA186E92 Q26781191-088FA2BA-ABEC-4BE2-86A1-A7F7D6D5631D Q26795463-20AA7451-2E7E-4EFF-B47B-D13340180188 Q27026631-E55FE559-E6DA-4D91-BA11-554EE322DA68 Q28075694-9D9540BE-5A4B-45AE-8D59-47C40AC25D8E Q28079455-773CEDB8-4B23-485C-863A-ED52BC18E499 Q28546901-75C1E003-3C4C-4FAC-8EE4-28287E8468A6 Q28546918-AA8AD244-9EB9-4DC6-9ACA-F3314221C5C3 Q33629133-2D476D0F-2F27-4ACF-A935-E1F69D3E45CB Q33654409-B42E1629-CBB1-41A7-BC30-04EAFCCF63CF Q33751386-23A49F2F-B275-4058-84C2-024F48C3885F Q34869380-0F1D6910-378F-43F0-ACC8-EFDDFD191382 Q36076018-EA1A0304-F794-47B2-AF86-CFB3E0CEFBC8 Q36108518-842D8ED0-5438-4D51-83B7-E048E9D34A22 Q36224979-B9FFFD76-DB0A-4E23-B1D5-B0ADF6FA03AC Q36515063-FDC090FC-8360-40A7-A540-3C767F56F672 Q36538827-395A473D-2166-4031-9E5D-38CD1088F24B Q36890640-57D9CC9B-A28C-4BAA-82AD-AA73E1C7E87C Q37144949-42F8955D-4A2B-4248-86D9-BE848FE69F42 Q37162797-E05969B1-0CF6-46C7-A931-EE319E6EE11A Q37325455-D9DA391F-06D6-4244-A104-B8C8657C2651 Q37522861-079DFA8E-43D6-446B-AD0E-801080960813 Q37661770-06DA102D-5A18-4E79-A933-BB8BC4B500F0 Q38458190-F1BCD525-4973-44F0-B62F-018A94428A20 Q38509230-2FED980A-2B1D-4E88-A46E-AF4BDBE529E0 Q38862056-EDB3BC5E-5947-4D9C-B139-13EC0DCDD99D Q38937709-E9697699-F687-4265-883F-B2782C95F056 Q38973362-BED04E9F-F1A5-42A0-866C-6416D2EE8A41 Q39153976-A5BE0BA4-5F65-4867-9690-47C3B6156BAC Q40054870-EF1FAEA7-1DE1-468B-A172-AF0483709788 Q40069803-39DA1F2F-F7EA-4533-AEA2-36BCFF9125BA Q40424592-668A9853-573F-48AF-B09D-CB0C6C1232EF Q46187533-61C2E5C4-6F32-40D6-9963-66375BF00D02 Q47548551-B449CF76-712C-4EBD-9E8F-88B00A65E146 Q47564917-8564B538-0CE7-41F5-B6B4-96223308B436 Q48113493-6C01B929-9C00-431D-B59A-285473A292C2 Q49851068-8F8A4A58-9325-475B-A8EE-4569AEFA49BA Q52816327-8D2BEF2A-931E-43A2-B44D-4334CB575823

P2860

Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling.

http://www.wikidata.org/entity/Q37041173

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Reactivation of HIV latency by ...... ein kinase Cδ-NF-κB signaling.

@en

Reactivation of HIV latency by ...... ein kinase Cδ-NF-κB signaling.

@nl

type

label

Reactivation of HIV latency by ...... ein kinase Cδ-NF-κB signaling.

@en

Reactivation of HIV latency by ...... ein kinase Cδ-NF-κB signaling.

@nl

prefLabel

Reactivation of HIV latency by ...... ein kinase Cδ-NF-κB signaling.

@en

Reactivation of HIV latency by ...... ein kinase Cδ-NF-κB signaling.

@nl

P1433

Q37041173-B8E24E66-2370-414E-B0A7-0AFFE8787F51

P1476

Q37041173-DDA91F12-EC5B-4F70-A6FC-9818730FA97F

P2093

Q37041173-01EE4DF7-9133-4F3D-83C2-AF031EDB16FB

Q37041173-0FE7D0CD-B4B6-4FC6-B723-2E4DF64E337F

Q37041173-2EFCDC48-E193-4C83-8955-9E34F3D934C7

Q37041173-3E8B1A72-6FC0-4B26-AE0D-C958BC00A8CE

Q37041173-41B83979-993C-4CED-91C8-37407BE37DDB

Q37041173-4D2D0196-A21F-43F9-B016-2FAE8DDEDA22

Q37041173-5D9C3E6D-3D37-47AF-AB2E-A8C8E8F8562B

Q37041173-5E89AD48-8032-43D6-B2C8-D99ABE93685E

Q37041173-94C87D87-D60B-4909-9345-935269BA8ABA

Q37041173-C9479302-67A7-4EC6-A5DF-D4D3E7B2602B

P2860

Q37041173-052099B0-1FA9-43FE-9C59-DA9A7FAA1D92

Q37041173-05F6CB93-917D-40F5-A26D-94FB3C1EA3E6

Q37041173-0B58C53C-C16A-4D44-8D8C-DDEEAB8C1BDE

Q37041173-0BD1E4E4-96C1-4991-B540-02D13F77EC0F

Q37041173-0CC9778E-D13B-4175-9445-B3EA679AEDC5

Q37041173-0DB13049-46E9-473F-94CE-6365FCE7A198

Q37041173-18C44BD7-4302-40F3-8B73-E141BB905C87

Q37041173-1BCDD73E-2284-44B0-95F2-29DFB0477D2B

Q37041173-1C3B2111-089F-4625-9240-0378D3003332

Q37041173-1CD77544-8DDC-4CAB-9352-26DE08510B32

P304

Q37041173-2F9FFDAA-A341-474C-99C4-49E7AC7604FC

P31

Q37041173-631F675F-B280-418A-9AA4-60CFA86C2F4A

P356

Q37041173-9DD026BE-B12B-4473-BEBA-86608E2DC38F

P407

Q37041173-07E9F3A0-FD61-4881-9923-6FBADE180CFE

P433

Q37041173-7E164287-5DB6-4E10-B4DB-C64C4E114E05

P478

Q37041173-05B6C040-0818-4E41-AED9-443EFBD1A678

P50

Q37041173-F2A14914-308C-4D60-8F39-51F1CF0E4664

P577

Q37041173-86D227DA-1F8D-4090-8D21-EE2FCBD9600D

P5875

Q37041173-0AB3C908-2984-4F25-9602-4480B156D9A3

P698

Q37041173-9DBC5634-4200-45BD-B240-9BC2A18C4BDD

P921

Q37041173-1677491A-C410-4371-8548-B4B2693124E3

Q37041173-EEB50800-4222-4A84-87E0-FF4EE63B625C

P932

Q37041173-37B6E370-ADD8-4F9B-832C-8E6C718E8C36

P356

QAD.0000000000000289

P1433

P1476

Reactivation of HIV latency by ...... ein kinase Cδ-NF-κB signaling.

@en

P2093

Erica A Mendes

http://www.w3.org/2001/XMLSchema#string

George R Thompson

http://www.w3.org/2001/XMLSchema#string

Greg P Melcher

http://www.w3.org/2001/XMLSchema#string

Guochun Jiang

http://www.w3.org/2001/XMLSchema#string

Joseph K Wong

http://www.w3.org/2001/XMLSchema#string

Luiz F Pianowski

http://www.w3.org/2001/XMLSchema#string

Mariana G Weber

http://www.w3.org/2001/XMLSchema#string

Philipp Kaiser

http://www.w3.org/2001/XMLSchema#string

Satya Dandekar

http://www.w3.org/2001/XMLSchema#string

Sumathi Sankaran-Walters

http://www.w3.org/2001/XMLSchema#string

P2860

Protein kinase D mediates a stress-induced NF-kappaB activation and survival pathway.

The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1.

Transcription elongation factor P-TEFb mediates Tat activation of HIV-1 transcription at multiple stages

A human immunodeficiency virus type 1 Tat-like arginine-rich RNA-binding domain is essential for HEXIM1 to inhibit RNA polymerase II transcription through 7SK snRNA-mediated inactivation of P-TEFb

Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid

Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells

Practical synthesis of prostratin, DPP, and their analogs, adjuvant leads against latent HIV

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

Mechanism of selective inhibition of human immunodeficiency virus by ingenol triacetate

P304

1555-1566

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAD.0000000000000289

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262146036

http://www.w3.org/2001/XMLSchema#string

P698

24804860

http://www.w3.org/2001/XMLSchema#string

P921

P932

4922310

http://www.w3.org/2001/XMLSchema#string